Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
25.47
+0.01 (0.04%)
At close: Dec 5, 2025, 4:00 PM EST
25.25
-0.22 (-0.86%)
After-hours: Dec 5, 2025, 5:48 PM EST
Lyell Immunopharma Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Lyell Immunopharma stock ranges from a low of $10 to a high of $20. The average analyst price target of $16.67 forecasts a -34.55% decrease in the stock price over the next year.
Price Target: $16.67 (-34.55%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lyell Immunopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $10 → $20 | Hold | Maintains | $10 → $20 | -21.48% | Nov 24, 2025 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | -21.48% | Sep 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $10 | Hold | Maintains | $1 → $10 | -60.74% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | -21.48% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | -21.48% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
22.95K
from 61.00K
Decreased by -62.38%
Revenue Next Year
n/a
from 22.95K
EPS This Year
-11.28
from -26.23
EPS Next Year
-9.23
from -11.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31,500 | n/a | |||
| Avg | 22,950 | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -48.4% | - | |||
| Avg | -62.4% | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -10.71 | -7.72 | |
| Avg | -11.28 | -9.23 | |
| Low | -11.68 | -9.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.